Which Fibrate, Which Patients, What Mechanism?
From the Heart Research Institute (P.J.B., K.-A.R.), and the Department of Medicine (P.J.B., K.-A.R.), University of Sydney, Sydney, and the Department of Medicine (K.-A.R.), University of Melbourne, Melbourne, Australia. Correspondence to Prof Philip Barter, The Heart Research Institute, 145 Missenden Rd, Camperdown, NSW 2050, Australia. E-mail barterp{at}hri.org.au’ + u + ‘@’ + d + ”//–> Key Words: Editorials cardiovascular diseases cholesterol lipoproteins trials Several large intervention trials have investigated the potential of fibrates to reduce cardiovascular events. The results have varied widely: positive, with gemfibrozil in the primary prevention Helsinki Heart Study (HHS)1 and the secondary prevention Veterans Administration High Density Lipoprotein Intervention Trial (VA-HIT)2; positive, with reservations related to an increase in noncardiovascular mortality in the primary prevention World Health Organization trial (clofibrate)3; and mixed, with bezafibrate in the secon
